Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O60841
UPID:
IF2P_HUMAN
Alternative names:
Translation initiation factor IF-2
Alternative UPACC:
O60841; O95805; Q53RV7; Q53SI8; Q9UF81; Q9UMN7
Background:
Eukaryotic translation initiation factor 5B (EIF5B) is a pivotal player in the process of translation initiation, facilitating the joining of the 60S ribosomal subunit to the pre-initiation complex. This action forms the 80S initiation complex, essential for protein synthesis. EIF5B's unique function, alongside eIF1A, in orienting the initiator methionine-tRNA, underscores its critical role in the efficient assembly of the initiation complex, a process fundamental to cellular protein production.
Therapeutic significance:
Understanding the role of Eukaryotic translation initiation factor 5B could open doors to potential therapeutic strategies.